Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Research & Development (2016 - 2025)

Historic Research & Development for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $3.7 million.

  • Mimedx's Research & Development rose 2690.2% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 2410.75%. This contributed to the annual value of $12.3 million for FY2024, which is 255.82% down from last year.
  • Latest data reveals that Mimedx reported Research & Development of $3.7 million as of Q3 2025, which was up 2690.2% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Research & Development registered a high of $6.0 million during Q1 2022, and its lowest value of -$4.7 million during Q4 2022.
  • For the 5-year period, Mimedx's Research & Development averaged around $3.1 million, with its median value being $3.5 million (2023).
  • In the last 5 years, Mimedx's Research & Development tumbled by 18264.41% in 2021 and then surged by 15145.94% in 2023.
  • Mimedx's Research & Development (Quarter) stood at -$2.8 million in 2021, then plummeted by 66.6% to -$4.7 million in 2022, then skyrocketed by 151.46% to $2.4 million in 2023, then surged by 46.77% to $3.6 million in 2024, then increased by 3.7% to $3.7 million in 2025.
  • Its Research & Development was $3.7 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.3 million in Q1 2025.